KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Treasury Shares: 2018-2024

Historic Treasury Shares for Aquestive Therapeutics (AQST) over the last 6 years, with Dec 2024 value amounting to $2.6 million.

  • Aquestive Therapeutics' Treasury Shares rose 6.01% to $2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.9 million, marking a year-over-year increase of 6.01%. This contributed to the annual value of $2.6 million for FY2024, which is 33.98% up from last year.
  • Aquestive Therapeutics' Treasury Shares amounted to $2.6 million in FY2024, which was up 33.98% from $1.9 million recorded in FY2023.
  • In the past 5 years, Aquestive Therapeutics' Treasury Shares ranged from a high of $2.6 million in FY2024 and a low of $14,000 during FY2020.
  • In the last 3 years, Aquestive Therapeutics' Treasury Shares had a median value of $1.9 million in 2023 and averaged $1.6 million.
  • Its Treasury Shares has fluctuated over the past 5 years, first slumped by 81.08% in 2020, then skyrocketed by 1,102.47% in 2023.
  • Yearly analysis of 4 years shows Aquestive Therapeutics' Treasury Shares stood at $14,000 in 2020, then reached $162,000 in 2022, then spiked by 1,102.47% to $1.9 million in 2023, then spiked by 33.98% to $2.6 million in 2024.